Company chart and information is provided by TradingView based on 15-minute-delayed data.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
| Website: | www.arrowheadpharma.com |
| Email: | ir@arrowheadpharma.com |
| Main Phone: | +1 626 304-3400 |
| Address: | 177 E. Colorado Boulevard |
| Address 2: | Suite 700 |
| State: | CA |
| City / Town: | Pasadena |
| Country: | US |
| Postal Code: | 91105 |
| Exchange: | NGS |
| CEO: | Christopher Anzalone |
| Employees: | 232 |
| NAICS: | Research and Development in Biotechnology (except Nanobiotechnology)(541714) |
We examine several stocks from a technical angle.
Is Abercrombie & Fitch breaking out?
A few names to know.
Spring Bank Pharmaceuticals (SBPH) is hitting clinical milestones in its search for a cure to hepatitis B virus, which affects 325 million people worldwide. (Image source: OnHealth)
Shares of Small-Cap Star Arrowhead Research Corp. (ARWR) are up sharply on Tuesday, with gains in excess of 15% in early trading. The move comes without any clear news item motivating the gains
The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will
You may not have thought to look northward for biotech innovators, but Bloom Burton & Co. cofounder and President Brian Bloom can show you some truly hot Canadian companies with compelling
Potential. That's what every investor is looking for in a biotech investment. Grant Zeng of Zacks Small-Cap Research zeroes in on three primary factors when he looks at whether a particular
Starting a new investment company and investing in very small biotechs can be a minefield. Because the business is fraught with bad science and liquidity traps, it takes insight and industry
Shares of small-cap biopharmaceutical company Arrowhead Research (ARWR) plunged more than 15 percent Monday on mysteriously negative trading. Arrowhead actually gapped up slightly to begin the
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
